Royalty Pharma plc (NASDAQ: RPRX) closed the day trading at $28.80 down -2.17% from the previous closing price of $29.44. In other words, the price has decreased by -$0.64 from its previous closing price. On the day, 3624797 shares were traded.
Ratios:
For a better understanding of RPRX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 25.97 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.24. For the most recent quarter (mrq), Quick Ratio is recorded 7.90 and its Current Ratio is at 7.90. In the meantime, Its Debt-to-Equity ratio is 0.94 whereas as Long-Term Debt/Eq ratio is at 0.94.
On May 13, 2022, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $53.
On April 27, 2022, Goldman started tracking the stock assigning a Buy rating and target price of $56.Goldman initiated its Buy rating on April 27, 2022, with a $56 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 04 ’24 when RIGGS RORY B sold 35,702 shares for $27.55 per share. The transaction valued at 983,504 led to the insider holds 20,099 shares of the business.
RIGGS RORY B sold 199,098 shares of RPRX for $5,532,276 on Jan 03 ’24. The Director now owns 55,801 shares after completing the transaction at $27.79 per share. On Jan 02 ’24, another insider, RIGGS RORY B, who serves as the Director of the company, sold 235,200 shares for $28.52 each. As a result, the insider received 6,707,081 and left with 254,899 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RPRX now has a Market Capitalization of 13.15B and an Enterprise Value of 18.05B. As of this moment, Royalty’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.36, and their Forward P/E ratio for the next fiscal year is 6.88. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.55. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.46 while its Price-to-Book (P/B) ratio in mrq is 1.97. Its current Enterprise Value per Revenue stands at 7.67 whereas that against EBITDA is 9.56.
Stock Price History:
Over the past 52 weeks, RPRX has reached a high of $36.74, while it has fallen to a 52-week low of $25.92. The 50-Day Moving Average of the stock is 29.84, while the 200-Day Moving Average is calculated to be 28.91.
Shares Statistics:
Over the past 3-months, RPRX traded about 2.63M shares per day on average, while over the past 10 days, RPRX traded about 1.84M shares per day. A total of 446.69M shares are outstanding, with a floating share count of 378.54M. Insiders hold about 15.26% of the company’s shares, while institutions hold 68.99% stake in the company. Shares short for RPRX as of Mar 15, 2024 were 12.65M with a Short Ratio of 4.81, compared to 11.5M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.83% and a Short% of Float of 2.95%.
Dividends & Splits
RPRX’s forward annual dividend rate is 0.81, up from 0.80 a year ago. Against a Trailing Annual Dividend Yield of 2.72%, it implies a Forward Annual Dividend Yield of 2.76%.
Earnings Estimates
Current recommendations for the stock of the company come from 5 analysts. On average, analysts expect EPS of $0.95 for the current quarter, with a high estimate of $1.07 and a low estimate of $0.83, while EPS last year was $1.6. The consensus estimate for the next quarter is $0.92, with high estimates of $0.99 and low estimates of $0.79.
Analysts are recommending an EPS of between $4.19 and $2.97 for the fiscal current year, implying an average EPS of $3.77. EPS for the following year is $4.12, with 7 analysts recommending between $4.74 and $2.8.
Revenue Estimates
4 analysts predict $665.57M in revenue for the current quarter. It ranges from a high estimate of $731.45M to a low estimate of $533.94M. As of the current estimate, Royalty Pharma plc’s year-ago sales were $852.9M, an estimated decrease of -22.00% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for RPRX’s current fiscal year. The highest revenue estimate was $2.79B, while the lowest revenue estimate was $2.39B, resulting in an average revenue estimate of $2.63B. In the same quarter a year ago, actual revenue was $2.35B, up 11.50% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $2.87B in the next fiscal year. The high estimate is $3.23B and the low estimate is $2.57B. The average revenue growth estimate for next year is up 9.40% from the average revenue estimate for this year.
